An observational study in Conjunctivitis, SARS-CoV-2 and COVID-19, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.
Sponsored by Johns Hopkins University · Observational
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified, highly contagious RNA virus causing respiratory infectious disease, Coronavirus Disease 2019 (COVID-19). Conjunctivitis has been reported as a rare finding of the disease, and preliminary studies showed that the virus RNA could be detected in ocular secretions using polymerase chain reaction (PCR) assays when conjunctivitis present. This study aims to estimate the proportion of SARS-CoV-2 associated conjunctivitis among patients with suspected viral conjunctivitis presented to the ophthalmology clinics of Wilmer Eye Institute during the COVID-19 pandemic. The investigators also aim to identify whether SARS-CoV-2 associated conjunctivitis is an isolated finding or an early sign of COVID-19.
85 studies on the registry are indexed under Conjunctivitis; 5 are open to participants now.
This study's enrollment of 36 is below the median of 254 across 18 observational studies indexed under Conjunctivitis.
Browse Conjunctivitis studies →Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients present or are referred to the ophthalmology clinic due to red eye complaints, suspected viral conjunctivitis, or keratoconjunctivitis will be consecutively approached and recruited if they show a willingness to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Proportion of conjunctival samples tested positive for SARS-CoV-2
Number of conjunctival samples with positive PCR divided by the total number of conjunctival samples
Time frame: 1 year
Proportion of nasal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples
Number of nasal samples with positive PCR divided by the number of conjunctival samples with positive PCR
Time frame: 1 year
Proportion of nasopharyngeal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples
Number of nasopharyngeal samples with positive PCR divided by the number of conjunctival samples with positive PCR
Time frame: 1 year
Rate of development of COVID-19 in the study patient population
Number of patients developed COVID-19 divided by the number of the study population
Time frame: 1 year
Positive conjunctival sample rate in patient developed COVID-19
Number of conjunctival samples with positive PCR divided by the number of patients developed COVID-19
Time frame: 1 year
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.